NCT06863935View on ClinicalTrials.gov

A Pilot Study of High-Dose Omega-3 (Soloways ™) Polyunsaturated Fatty Acids in Patients with Dyslipidemia Carrying FADS1/FADS2 Variants

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 10, 2024

Primary Completion Date

September 19, 2024

Study Completion Date

January 18, 2025

Conditions
Dyslipidemia
Interventions
DIETARY_SUPPLEMENT

High-dose omega-3 PUFA supplementation

High-dose omega-3 PUFA supplementation (2-4 g/day EPA+DHA) for 12 weeks in addition to standard lipid-lowering therapy

DIETARY_SUPPLEMENT

High-dose omega-3 PUFA supplementation

High-dose omega-3 PUFA supplementation (2-4 g/day EPA+DHA) for 12 weeks in addition to standard lipid-lowering therapy

Trial Locations (1)

630090

Center for New Medical Techologies, Novosibirsk

All Listed Sponsors
collaborator

Center for New Medical Technologies, Novosibirsk, Russia

OTHER

lead

S.LAB (SOLOWAYS)

OTHER

NCT06863935 - A Pilot Study of High-Dose Omega-3 (Soloways ™) Polyunsaturated Fatty Acids in Patients with Dyslipidemia Carrying FADS1/FADS2 Variants | Biotech Hunter | Biotech Hunter